18F-FDG PET/CT与肿瘤标志物NSE和ProGRP在小细胞肺癌诊疗中的应用
The application of 18 F-FDG PET/CT with tumor markers NSE and ProGRP in the diagnosis and treatment of small cell lung cancer
林帅 1王艳丽1
作者信息
- 1. 青岛市中心医院分子影像科PET/CT中心,山东青岛 266042
- 折叠
摘要
小细胞肺癌(small cell lung cancer,SCLC)是肺内最常见的神经内分泌肿瘤,恶性程度高,易复发、易转移.改善SCLC患者预后的关键在于疾病的早期诊断、正确分期以及准确评估疗效和预后.本文通过对18F-氟代脱氧葡萄糖(FDG)PET/CT、肿瘤标志物神经元特异性烯醇化酶(NSE)和胃泌素释放肽前体(ProGRP)在SCLC诊疗方面的应用进展进行综合分析,以期为临床上SCLC患者的诊疗提供帮助.
Abstract
Small cell lung cancer(SCLC)is the most common neuroendocrine tumor in the lungs.SCLC is characterized by high malignancy and high recurrence and metastasis rates.The improvement of the prognosis of patients with SCLC relies on early diagnosis,correct staging,and accurate assessment of efficacy and prognosis.In this paper,we comprehensively analyze the application progress of 18F-fluorodeoxyglucose(FDG)PET/CT as well as the tumor markers neuron-specific enolase(NSE)and gastrin-releasing peptide precursor(ProGRP)in the diagnosis and treatment of SCLC.Our results can be useful for the diagnosis and treatment of SCLC patients in clinical practice.
关键词
小细胞肺癌/氟脱氧葡萄糖F18/正电子发射断层显像计算机体层摄影术/磷酸丙酮酸水合酶/胃泌素释放肽/蛋白质前体/生物标记,肿瘤Key words
Small cell lung carcinoma/Fluorodeoxyglucose F18/Positron emission tomography computed tomography/Phosphopyruvate hydratase/Gastrin-releasing peptide/Protein precursors/Biomarkers,tumor引用本文复制引用
基金项目
青岛市医药卫生科研计划项目(2021-WJZD067)
出版年
2024
国家科技期刊平台
NSTL
万方数据